GO:0004063 aryldialkylphosphatase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004063 aryldialkylphosphatase activity catalyzes the hydrolysis of aryl dialkyl phosphates to dialkyl phosphate and an aryl alcohol, and is best known as paraoxonase/phosphotriesterase activity.
• The paraoxonase (PON) family, especially PON1, PON2 and PON3, are the principal mammalian enzymes annotated with this activity and also display lactonase and esterase activities toward diverse substrates.
• PON1 is tightly associated with high-density lipoprotein (HDL) and contributes to HDL maturation and antioxidant protection, linking GO:0004063 to cardiovascular and metabolic biology.
• Altered aryldialkylphosphatase/paraoxonase activity is reported in neurological disorders, xenobiotic exposure and non-alcoholic steatohepatitis, making it a biomarker and potential therapeutic target.
• PON2 agonism with vutiglabridin promotes autophagy and mitochondrial function, showing that modulating this activity can alleviate experimental steatohepatitis.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of PON genes and other aryldialkylphosphatase-annotated enzymes in disease and toxicology.
Description
GO:0004063 aryldialkylphosphatase activity is a molecular function defined by the catalytic reaction aryl dialkyl phosphate + H2O = dialkyl phosphate + an aryl alcohol. This activity is widely known as paraoxonase, phosphotriesterase or organophosphate hydrolase activity, and it is central to the detoxification of organophosphate compounds and to the metabolism of certain lactones and esters. Researchers study GO:0004063 because it connects environmental toxicology, lipoprotein biology and redox regulation of the immune response. The paraoxonase family, particularly PON1, PON2 and PON3, provides the best-characterized mammalian examples of enzymes carrying this activity, although the GO term itself is not restricted to a single protein family. Because the same enzymes can hydrolyze organophosphates, lactones and other esters, GO:0004063 sits at the intersection of xenobiotic detoxification, antioxidant defense and lipid metabolism. Understanding this activity therefore requires integrating enzymology, substrate specificity, genetic variation and disease association data from human and model-system studies.
aryldialkylphosphatase activity At A Glance
| GO ID | GO:0004063 |
|---|---|
| GO term | aryldialkylphosphatase activity |
| Ontology | molecular_function |
| Definition | Catalysis of the reaction: aryl dialkyl phosphate + H2O = dialkyl phosphate + an aryl alcohol. |
| Synonyms | A-esterase activity; aryltriphosphatase activity; aryltriphosphate dialkylphosphohydrolase activity; esterase B1; esterase E4; OPH; organophosphate esterase activity; organophosphate hydrolase activity; organophosphorus acid anhydrase activity; organophosphorus hydrolase activity; paraoxonase activity; paraoxon esterase activity; paraoxon hydrolase activity; phosphotriesterase activity; pirimiphos-methyloxon esterase activity |
| Major function | Hydrolysis of aryl dialkyl phosphates and related organophosphate esters, contributing to xenobiotic detoxification and lipid/lactone metabolism. |
| Representative enzymes | Paraoxonase 1 (PON1), paraoxonase 2 (PON2) and paraoxonase 3 (PON3) in mammals. |
| Associated biology | HDL maturation, antioxidant defense, redox regulation of immune response and xenobiotic exposure responses. |
| Disease relevance | Neurological disorders, non-alcoholic steatohepatitis and cardiovascular/metabolic phenotypes have been linked to altered paraoxonase activity. |
What Is GO:0004063?
In my own words, GO:0004063 aryldialkylphosphatase activity describes the ability of an enzyme to use water to cleave an aryl dialkyl phosphate substrate, releasing a dialkyl phosphate and an aryl alcohol. The term covers enzymes historically called paraoxonases, phosphotriesterases and organophosphate hydrolases, reflecting their capacity to hydrolyze organophosphate esters such as paraoxon. This activity is a molecular function, not a process or a location, and it can be measured with synthetic or natural substrates including paraoxon, phenyl acetate and lactones.
Why Is aryldialkylphosphatase activity Important in Cell Biology?
GO:0004063 aryldialkylphosphatase activity matters because it defines the enzymatic capacity to detoxify organophosphate compounds and to process endogenous lactones and esters that influence oxidative stress and inflammation. Paraoxonase enzymes carrying this activity are physically and functionally linked to HDL, so changes in their activity can report on lipoprotein quality and cardiovascular risk. In toxicology, paraoxonase activity is used as a marker of exposure to xenobiotics such as those in tobacco smoke, and it modulates susceptibility to organophosphate toxicity. In neurobiology, paraoxonase 1 has been studied in relation to neurological disorders, where oxidative stress and lipid peroxidation are prominent. In metabolic disease, pharmacological activation of PON2 with vutiglabridin promotes autophagy and mitochondrial function and alleviates experimental non-alcoholic steatohepatitis, demonstrating that this activity is druggable. Finally, because the same catalytic scaffold can accept multiple substrates, GO:0004063 is a paradigm for understanding enzyme promiscuity and for engineering biocatalysts.
• Provides a biochemical defense against organophosphate xenobiotics and pesticides.
• Supports HDL maturation and antioxidant functions in lipoprotein metabolism.
• Modulates oxidative stress and redox regulation of immune responses.
• Is a candidate biomarker and mechanistic contributor in neurological disorders.
• Is pharmacologically tractable, as shown by PON2 agonist vutiglabridin in steatohepatitis models.
• Exhibits broad substrate promiscuity toward lactones and esters, relevant to drug metabolism.
• Enables toxicological monitoring of exposure to tobacco smoke and other xenobiotics.
• Offers a model system for studying enzyme evolution and phosphotriesterase engineering.
• Connects genetic variation in PON genes to inter-individual differences in detoxification capacity.
• Supports CRISPR-based causal studies of PON gene function in human cells and animal models.
Molecular Mechanism of aryldialkylphosphatase activity
Substrate recognition and binding
In simple terms: The enzyme first grabs the organophosphate or lactone substrate in a pocket that can accommodate different shapes.
Aryldialkylphosphatase enzymes such as PON1 bind substrates including paraoxon, phenyl acetate and various lactones through a hydrophobic active-site channel that accommodates aryl and alkyl groups. Substrate specificity is not absolute; the same enzyme can hydrolyze organophosphate triesters, lactones and aromatic esters, which is why GO:0004063 is associated with several synonymous activities. Structural and kinetic studies indicate that the size and polarity of the substrate influence catalytic efficiency, and naturally occurring polymorphisms in PON1 can shift substrate preference.
Catalytic hydrolysis of the phosphoester bond
In simple terms: Water is used to break the phosphate ester bond, releasing a dialkyl phosphate and an aryl alcohol.
The defining reaction of GO:0004063 is the hydrolysis of an aryl dialkyl phosphate to a dialkyl phosphate and an aryl alcohol. This reaction proceeds through nucleophilic attack of water or hydroxide on the phosphorus center, with active-site residues stabilizing the transition state. For paraoxon, the products are diethyl phosphate and p-nitrophenol, a convenient chromogenic readout used in enzyme assays. The same catalytic machinery can hydrolyze lactones, which has led to the view that lactonase activity may be the ancestral and physiologically relevant function of paraoxonases.
Calcium dependence and structural stabilization
In simple terms: The enzyme needs calcium ions to keep its shape and to work properly.
Mammalian paraoxonases are calcium-dependent enzymes; calcium ions are required for structural integrity and catalytic activity. Removal of calcium or chelation leads to loss of aryldialkylphosphatase activity, and the calcium-binding sites are conserved across PON family members. This dependence distinguishes PON enzymes from some bacterial phosphotriesterases that use different metal cofactors, and it is an important consideration when designing assays or purification protocols.
Regulation by genetic variation and environment
In simple terms: How well the enzyme works depends on inherited variants and on lifestyle or chemical exposures.
PON1 activity is modulated by coding and promoter polymorphisms, including the Q192R and L55M variants, which affect substrate-dependent catalytic rates and enzyme abundance. Environmental factors such as smoking and exposure to xenobiotics can also alter paraoxonase activity, making it a useful marker of exposure. Multi-omics analyses have linked PON1 lactonase activity to human health and disease states, suggesting that regulation occurs at genetic, transcriptional and post-translational levels. Redox conditions can further influence enzyme function and the broader immune response in which these enzymes participate.
Association with HDL particles
In simple terms: In blood, the enzyme often travels attached to HDL particles, which affects what it can do.
PON1 is physically associated with high-density lipoprotein (HDL) particles, and this association is important for its stability and antioxidant functions. HDL maturation involves remodeling of lipoprotein particles, and PON1 is one of the proteins that co-transport with HDL during this process. The HDL-bound state can influence substrate access and protection against oxidative modification of lipids, linking GO:0004063 to cardiovascular biology. PON2 and PON3 are also expressed in tissues and have distinct subcellular distributions, but they share the catalytic activity defined by GO:0004063.
Key Genes Involved in GO:0004063 aryldialkylphosphatase activity
The following genes encode enzymes or associated proteins most frequently studied in the context of GO:0004063 aryldialkylphosphatase activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PON1 | Paraoxonase 1; HDL-associated enzyme with aryldialkylphosphatase, lactonase and esterase activities | Cardiovascular disease, organophosphate detoxification, biomarker studies |
| PON2 | Paraoxonase 2; intracellular enzyme with lactonase and aryldialkylphosphatase activity | Autophagy, mitochondrial function, non-alcoholic steatohepatitis |
| PON3 | Paraoxonase 3; HDL-associated enzyme with lactonase activity | Lipoprotein metabolism and antioxidant defense |
| PON1 Q192R variant | Common coding polymorphism altering substrate-dependent catalytic efficiency | Inter-individual differences in detoxification and disease risk |
| PON1 L55M variant | Promoter/coding variant influencing PON1 expression and activity | Association studies in neurological and metabolic disorders |
| ApoA1 | Major HDL apolipoprotein that interacts with PON1 | HDL maturation and PON1 stability |
| ApoE | Lipoprotein apolipoprotein influencing HDL and PON1 biology | Neurodegeneration and lipid metabolism |
| ABCA1 | Cholesterol transporter involved in HDL biogenesis | HDL maturation and PON1 association |
| LCAT | Lecithin-cholesterol acyltransferase in HDL remodeling | HDL maturation and PON1 function |
| CETP | Cholesteryl ester transfer protein affecting HDL composition | Lipoprotein metabolism and PON1 activity |
| Nrf2 (NFE2L2) | Transcription factor regulating antioxidant responses | Redox regulation and PON gene expression |
| NF-kB | Transcription factor in inflammatory signaling | Redox regulation of immune response |
| MAP1LC3B (LC3B) | Autophagy marker | PON2-mediated autophagy activation |
| SQSTM1 (p62) | Autophagy receptor | PON2 agonist studies in steatohepatitis |
| PPAR-alpha | Nuclear receptor regulating lipid metabolism | Metabolic regulation of paraoxonase activity |
| PPAR-gamma | Nuclear receptor regulating insulin sensitivity and lipid metabolism | Metabolic disease and PON2 biology |
| SOD1 | Superoxide dismutase 1; antioxidant enzyme | Redox regulation and oxidative stress |
| CAT | Catalase; antioxidant enzyme | Redox regulation and oxidative stress |
How Is aryldialkylphosphatase activity Regulated?
Aryldialkylphosphatase activity is regulated at multiple levels. Genetic polymorphisms in PON1, such as Q192R and L55M, alter catalytic efficiency and enzyme abundance in a substrate-dependent manner. Transcriptional regulation involves antioxidant and metabolic transcription factors, including Nrf2 and PPARs, which respond to oxidative stress and lipid status. Environmental exposures, including tobacco smoke and other xenobiotics, can modify paraoxonase activity, making it a dynamic marker of exposure. Post-translational regulation includes calcium-dependent stabilization and association with HDL particles, which influence enzyme stability and substrate access. Redox conditions and inflammatory signaling can further modulate the enzyme's environment and function.
aryldialkylphosphatase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PON1 | Cardiovascular disease and organophosphate toxicity | PON1 knockout and knock-in human cell lines; HDL-associated activity assays |
| PON2 | Non-alcoholic steatohepatitis and autophagy dysfunction | PON2 overexpression and point-mutation models in hepatocytes; vutiglabridin treatment |
| PON1 | Neurological disorders with oxidative stress | Neuronal cell lines with PON1 knockout or overexpression; oxidative stress challenge |
| PON3 | Lipoprotein metabolism and antioxidant defense | PON3 knockout and tagged knock-in models; HDL maturation assays |
| PON1 | Xenobiotic exposure biomarker | Reporter cell lines and enzyme activity assays after xenobiotic treatment |
Neurological disorders and oxidative stress
Paraoxonase 1 has been studied in neurological disorders where oxidative stress and lipid peroxidation contribute to pathology. Altered PON1 activity may influence susceptibility to neurotoxicity from organophosphates and endogenous oxidized lipids. Because PON1 is associated with HDL, changes in its activity can also reflect systemic metabolic and inflammatory states relevant to neurodegeneration.
Non-alcoholic steatohepatitis and metabolic disease
PON2 agonism with vutiglabridin promotes autophagy activation and improves mitochondrial function, alleviating experimental non-alcoholic steatohepatitis. This demonstrates that enhancing aryldialkylphosphatase-related enzyme function can have therapeutic benefits in metabolic liver disease. PON1 lactonase activity has also been linked to human health and disease states through multi-omics analyses, supporting a broader role in metabolic regulation.
Cardiovascular disease and HDL biology
PON1 is associated with HDL and contributes to HDL maturation and antioxidant protection, linking GO:0004063 to cardiovascular risk. Reduced paraoxonase activity has been observed in conditions associated with oxidative stress and inflammation, which are common in cardiovascular disease. The HDL-bound state of PON1 is thought to be important for its protective functions against lipid peroxidation.
Xenobiotic exposure and toxicology
Paraoxonase activity serves as a marker of exposure to xenobiotics, including those present in tobacco smoke. Inter-individual differences in PON1 activity can influence susceptibility to organophosphate toxicity, making this activity relevant to occupational and environmental health. Measuring aryldialkylphosphatase activity can therefore inform risk assessment and biomonitoring strategies.
From aryldialkylphosphatase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PON1 alter organophosphate detoxification? | PON1 knockout cell line or animal model with paraoxonase activity assay |
| Does a specific PON1 polymorphism change substrate specificity? | Point-mutation knock-in of Q192R or L55M in human cell lines |
| Can PON2 activation rescue steatohepatitis phenotypes? | PON2 overexpression and agonist treatment in hepatocyte models |
| How does PON1 association with HDL affect its activity? | Tagged knock-in of PON1 to track HDL binding and activity |
| What is the effect of PON3 on lipoprotein metabolism? | PON3 knockout and overexpression in liver-derived cells |
| Which transcription factors regulate PON1 expression? | Reporter knock-in and CRISPR interference at PON1 regulatory regions |
How to Study the aryldialkylphosphatase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Paraoxonase activity assay | Hydrolysis of paraoxon to p-nitrophenol | Comparing PON1 variants and knockout cells |
| Lactonase activity assay | Hydrolysis of lactone substrates | Assessing substrate promiscuity and physiological relevance |
| Genotyping (Q192R, L55M) | PON1 coding variants | Association studies and personalized risk assessment |
| Western blot | PON protein abundance | Validating knockout and overexpression models |
| Immunofluorescence | Subcellular localization and HDL association | Tracking tagged PON proteins in cells |
| RNA-seq | Transcriptional changes after PON modulation | Identifying regulatory networks and disease pathways |
| Proteomics | Protein interactions and HDL composition | Understanding PON1-containing lipoprotein particles |
| Autophagy flux assay | LC3 turnover and p62 levels | Evaluating PON2 agonist effects in steatohepatitis models |
Enzymatic activity assays
Aryldialkylphosphatase activity is commonly measured using paraoxon or phenyl acetate as substrates, with spectrophotometric detection of product formation. These assays can be applied to serum, cell lysates or purified enzyme and are useful for comparing wild-type and mutant enzymes. Lactonase activity assays using dihydrocoumarin or other lactones provide complementary information on substrate promiscuity.
Genetic and multi-omics analysis
Genotyping of PON1 polymorphisms and multi-omics profiling of PON1 lactonase activity can link genotype to enzyme function and disease states. Transcriptomic and proteomic analyses help identify regulatory networks involving Nrf2, PPARs and inflammatory pathways. Integrating these data with clinical phenotypes supports biomarker discovery and causal inference.
Cell-based models and imaging
CRISPR-engineered cell lines with PON gene knockouts, point mutations or tags enable mechanistic studies of GO:0004063 in a controlled background. Fluorescent tagging of PON proteins allows imaging of subcellular localization and HDL association. Autophagy and mitochondrial function can be monitored in PON2-modulated cells using standard reporters and imaging.
Animal and translational studies
Animal models with altered PON expression or activity are used to test the impact of aryldialkylphosphatase activity on toxicology, cardiovascular and metabolic phenotypes. Pharmacological tools such as vutiglabridin provide proof of concept for target engagement in vivo. Translational studies measure paraoxonase activity in human samples as a marker of exposure or disease risk.
How CRISPR Can Be Used to Study GO:0004063 aryldialkylphosphatase activity
Knockout
CRISPR knockout of PON1, PON2 or PON3 eliminates aryldialkylphosphatase activity in the targeted cells, enabling loss-of-function studies on detoxification, HDL biology and oxidative stress. Knockout models are essential for distinguishing the contributions of individual PON family members to GO:0004063-related phenotypes. They also provide clean backgrounds for re-expression or rescue experiments.
Point Mutation
Point-mutation knock-in of PON1 variants such as Q192R or L55M allows precise testing of how single amino acid changes alter substrate specificity and catalytic efficiency. These models are valuable for linking genotype to enzyme function and disease risk. They also help validate pharmacogenetic hypotheses in a controlled isogenic background.
Knock-in
Knock-in of tagged PON1 or PON2 (e.g., fluorescent or epitope tags) enables tracking of protein localization, HDL association and turnover without altering endogenous regulation. Knock-in of disease-associated variants or regulatory elements can model human genetic diversity. These models support imaging and interaction studies relevant to GO:0004063.
Overexpression
Overexpression of PON1, PON2 or PON3 increases aryldialkylphosphatase activity and can protect cells from oxidative and organophosphate stress. PON2 overexpression has been used to study autophagy activation and mitochondrial function in steatohepatitis models. Overexpression systems are also useful for producing recombinant enzyme for biochemical and structural studies.
How EDITGENE Supports aryldialkylphosphatase activity Research
Researchers studying aryldialkylphosphatase activity-related genes often need to determine whether a candidate gene is causally involved in detoxification, lipoprotein biology or metabolic disease. EDITGENE provides CRISPR-based cell model services that allow precise manipulation of PON genes and other enzymes annotated with GO:0004063, from complete knockout to single-base correction and tagged knock-in.
Contact EDITGENE today to design your custom CRISPR model for aryldialkylphosphatase activity research.
Frequently Asked Questions About aryldialkylphosphatase activity
What is aryldialkylphosphatase activity?
Aryldialkylphosphatase activity (GO:0004063) is a molecular function that catalyzes the hydrolysis of aryl dialkyl phosphates to dialkyl phosphate and an aryl alcohol, and is commonly known as paraoxonase or phosphotriesterase activity.
What genes are involved in aryldialkylphosphatase activity?
The main human genes are PON1, PON2 and PON3, which encode paraoxonase enzymes with aryldialkylphosphatase, lactonase and esterase activities.
What is the difference between PON1, PON2 and PON3?
PON1 is primarily HDL-associated and studied in cardiovascular and toxicology contexts, PON2 is intracellular and linked to autophagy and metabolic disease, and PON3 is HDL-associated with lactonase activity.
How is aryldialkylphosphatase activity measured?
It is typically measured using paraoxon or phenyl acetate as substrates in spectrophotometric assays, and lactone substrates are used to assess lactonase activity.
What diseases are associated with altered paraoxonase activity?
Altered paraoxonase activity has been linked to cardiovascular disease, neurological disorders, non-alcoholic steatohepatitis and susceptibility to organophosphate toxicity.
What is the role of PON1 in HDL biology?
PON1 is associated with HDL particles and contributes to HDL maturation and antioxidant protection, linking GO:0004063 to lipoprotein metabolism.
Can CRISPR be used to study aryldialkylphosphatase activity?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models allow precise manipulation of PON genes to study their causal roles in detoxification and disease.
What is the Q192R polymorphism in PON1?
Q192R is a common coding variant in PON1 that alters substrate-dependent catalytic efficiency and has been studied in relation to disease risk and detoxification capacity.
Is paraoxonase activity a biomarker of xenobiotic exposure?
Yes, paraoxonase activity has been used as a marker of exposure to xenobiotics, including tobacco smoke components.
What drugs target paraoxonase-related pathways?
Vutiglabridin is a PON2 agonist that promotes autophagy and mitochondrial function and alleviates experimental non-alcoholic steatohepatitis.
Conclusion
GO:0004063 aryldialkylphosphatase activity defines a versatile enzymatic function with broad relevance to xenobiotic detoxification, lipoprotein biology, oxidative stress and metabolic disease. The paraoxonase family provides the best-characterized examples, and genetic variation in PON1, PON2 and PON3 influences enzyme activity and disease susceptibility. CRISPR-based models are powerful tools for dissecting the causal roles of these enzymes and for testing therapeutic strategies targeting this activity.
References
- 1. Morris G et al.. 2022. Redox regulation of the immune response.. Cell Mol Immunol 19(10):1079-1101 PMID: 36056148
- 2. Costa LG et al.. 2005. Modulation of paraoxonase (PON1) activity.. Biochem Pharmacol 69(4):541-50 PMID: 15670573
- 3. Mu X et al.. 2018. Substrates for Paraoxonase.. Curr Pharm Des 24(5):615-627 PMID: 29237378
- 4. Shin GC et al.. 2024. Paraoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis.. Br J Pharmacol 181(19):3717-3742 PMID: 38852992
- 5. Gugliucci A et al.. 2015. Paraoxonase 1 and HDL maturation.. Clin Chim Acta 439:5-13 PMID: 25261854
- 6. Menini T et al.. 2014. Paraoxonase 1 in neurological disorders.. Redox Rep 19(2):49-58 PMID: 24225313
- 7. Milnerowicz H et al.. 2015. Paraoxonase activity as a marker of exposure to xenobiotics in tobacco smoke.. Int J Toxicol 34(3):224-32 PMID: 25953737
- 8. Petrič B et al.. 2021. A Multi-Omics Analysis of PON1 Lactonase Activity in Relation to Human Health and Disease.. OMICS 25(1):38-51 PMID: 33306925
